Cognex Corp (CGNX) Tops Q1 EPS by 2c; Guides Q2 Revs Below Views
Tweet
Share
E-mailGet Alerts CGNX Hot Sheet
Price: $60.67 --0%
Financial Fact:
Research, development, and engineering expenses: 18.6M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Research, development, and engineering expenses: 18.6M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Cognex Corp (NASDAQ: CGNX) reported Q1 EPS of $0.33, $0.02 better than the analyst estimate of $0.31. Revenue for the quarter came in at $77.71 million versus the consensus estimate of $75.92 million.
Sees Q2 2012 revenue of $82-$85 million, versus the consensus of $85.99 million.
For earnings history and earnings-related data on Cognex Corp (CGNX) click here.
Sees Q2 2012 revenue of $82-$85 million, versus the consensus of $85.99 million.
For earnings history and earnings-related data on Cognex Corp (CGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c
- Pelthos Therapeutics Inc. (PTHS) Misses Q2 EPS by 611c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
